Science Hub
Welcome to Novo Nordisk Science Hub
The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.
Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.
By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.
Ildiko Lingvay is Professor in the Division of Endocrinology and the
Department of Population and Data Sciences at the University of Texas
(UT) Southwestern Medical Center in Dallas, TX, USA. She also serves
as Medical Director of the Office of Clinical Trials Management
overseeing the institutional review and approval of all clinical
studies and clinical trials at UT Southwestern. She sees patients at
the university clinics and hospital, as well as at the Parkland Health
System.
Dr Lingvay leads a clinical research
programme in the field of obesity, diabetes and associated metabolic
complications with the ultimate goal of improving the lives of all
patients who suffer from the many health consequences of these
conditions. Her research interests span the spectrum from
pathophysiology of the disease to comparative effectiveness of
therapeutic approaches. She has participated in many clinical trials
in the field and has a special interest in cardiovascular trials in
diabetes and obesity. She has published over 100 manuscripts in major
medical journals and has contributed to several diabetes textbooks.
She is an active member of the American Diabetes Association, where
she served on the Scientific Sessions Organizing Committee and
currently is on the grant review committee and a board member of the
WIN ADA and Focus on Fellows initiatives.
